Park Soon Jae

Age: 71
Residence: Daejeon, South Korea
Citizenship: South Korea
Marital Status: Married
Education: Ph.D., Purdue University
Key Milestone: 2024 Merck licensing deal for ALT-B4 with pembrolizumab
Company: Alteogen (founded 2008)
Role: Cofounder & CEO
Industry Focus: Biosimilars, Bio-betters, Drug Delivery Platforms

Did you know? Before founding Alteogen, Park worked at LG Life Sciences and Hanwha Petrochemical, and was a postdoctoral researcher at MIT — experiences that shaped his dual focus on scientific rigor and commercial scalability. His wife, Chung Hye-shin, serves as Alteogen’s Chief Scientific Officer, making their partnership both personal and professional.

Age: 71
Source of Wealth: Biopharmaceuticals, Self-Made
Residence: Daejeon, South Korea
Citizenship: South Korea
Marital Status: Married
Education: Ph.D., Purdue University

Park’s educational background at Purdue University provided him with a strong foundation in biochemical engineering or a related field — a common trait among biotech founders who bridge the gap between laboratory science and industrial application. His postdoctoral work at MIT further exposed him to cutting-edge research environments, likely influencing his approach to innovation at Alteogen.

His career path — from corporate roles at LG Life Sciences and Hanwha Petrochemical to cofounding a biotech startup — reflects a deliberate transition from established industry to entrepreneurial leadership. This trajectory is typical of self-made billionaires in the life sciences, who often leverage corporate experience to identify unmet market needs and build scalable solutions.

At 71, Park remains actively involved in Alteogen’s leadership, a testament to his enduring commitment to the company’s mission. His wealth is not derived from inherited assets or passive investments, but from the creation and commercialization of proprietary technology — a hallmark of true self-made success in the biopharmaceutical sector.

As of April 2025, Park Soon-jae’s net worth is estimated at $1.3 billion, according to . He ranks #1375 globally and #14 among South Korea’s 50 Richest individuals. His wealth is primarily derived from his ownership stake in Alteogen, a South Korean biotechnology firm he co-founded in 2008 and currently leads as CEO. The company’s valuation is heavily influenced by its proprietary enzyme technology, ALT-B4, which enables subcutaneous delivery of biologics — a significant innovation in drug administration that reduces patient burden and healthcare costs.

Alteogen’s market capitalization surged following its 2024 licensing agreement with Merck, which granted the pharmaceutical giant rights to use ALT-B4 in conjunction with pembrolizumab, a blockbuster cancer immunotherapy. The announcement triggered a 25% single-day spike in Alteogen’s stock price, reflecting investor confidence in the technology’s commercial potential. Park’s personal stake, while not publicly quantified in the provided data, is presumed to be substantial given his role as co-founder and CEO. His wife, Chung Hye-shin, serves as Chief Scientific Officer and holds a smaller stake, indicating a shared professional and financial commitment to the company’s mission.

Biotech valuations are inherently volatile, driven by clinical trial outcomes, regulatory approvals, and licensing deals. Unlike traditional industries, biotech wealth is often tied to intellectual property and pipeline progress rather than current revenue. Alteogen’s value proposition rests on its ability to license ALT-B4 to global pharmaceutical companies, which pay upfront fees, milestone payments, and royalties. This model creates asymmetric upside: minimal capital expenditure for Alteogen, but outsized returns if partnered drugs succeed commercially. Park’s net worth, therefore, is not static — it fluctuates with Alteogen’s stock performance and the perceived likelihood of future licensing deals or regulatory milestones.

It is important to note that private biotech valuations, especially those of pre-revenue or early-commercial-stage firms, are subject to wide margins of error. Public market reactions, such as the 25% jump in 2024, often reflect sentiment rather than fundamental value. Park’s wealth may also include other assets — real estate, private investments, or equity in other ventures — but these are not disclosed in the provided data. His inclusion in ’ global billionaire list suggests his stake in Alteogen alone is sufficient to cross the $1 billion threshold, a rare feat for biotech entrepreneurs outside the U.S. or Europe.

Park Soon-jae’s wealth trajectory is inextricably linked to the rise of Alteogen, a company he co-founded in 2008 after a career in industrial chemistry and academic research. Prior to launching Alteogen, Park held positions at LG Life Sciences and Hanwha Petrochemical, and completed postdoctoral work at MIT — experiences that likely informed his approach to biotech innovation. The company’s early years were likely characterized by heavy R&D investment, minimal revenue, and reliance on venture capital or government grants — typical for biotech startups in South Korea, where the industry was less mature than in the U.S. or Japan.

The turning point in Park’s wealth accumulation came with the development and validation of ALT-B4, an enzyme technology that enables subcutaneous administration of biologics. This innovation addressed a critical pain point in oncology and autoimmune disease treatment: the need for less invasive, more convenient drug delivery. By 2024, Alteogen had advanced ALT-B4 to the point where it attracted the attention of Merck, one of the world’s largest pharmaceutical companies. The licensing deal, while terms were not disclosed, likely included upfront payments, development milestones, and royalties — a structure that can generate hundreds of millions in revenue for the licensor if the partnered drug succeeds.

The immediate market reaction to the Merck deal — a 25% single-day stock surge — suggests that investors viewed the partnership as a de-risking event, validating Alteogen’s technology and opening the door to additional licensing agreements. For Park, this translated into a significant paper wealth increase, assuming he retained a substantial equity stake. His inclusion in ’ 2025 rankings as #14 in Korea and #1375 globally indicates that his net worth crossed the billion-dollar threshold around this time, likely due to the valuation uplift from the Merck deal.

Biotech wealth is rarely linear. Park’s net worth may have experienced periods of stagnation or decline during Alteogen’s early, pre-commercial phase, followed by rapid appreciation as clinical and commercial milestones were achieved. The 2024 Merck deal represents a classic “inflection point” in biotech entrepreneurship: a validation event that transforms a promising technology into a commercially viable asset. Future wealth growth will depend on whether Alteogen can replicate this success with other partners or expand ALT-B4’s application to additional drug classes. Park’s age — 71 as of 2025 — may also influence his wealth strategy, potentially leading to partial exits or succession planning, though no such actions are disclosed in the provided data.

It is also worth noting that biotech wealth is often concentrated in a single asset — the company itself. Unlike diversified entrepreneurs, Park’s net worth is likely heavily exposed to Alteogen’s stock performance. This creates both opportunity and risk: if Alteogen’s pipeline expands and additional licensing deals are secured, his wealth could grow substantially. Conversely, if clinical trials fail or regulatory hurdles arise, the stock — and his net worth — could decline sharply. The absence of public data on his personal holdings or diversification makes it difficult to assess the full scope of his financial exposure.

Park Soon-jae operates within a global ecosystem of biopharmaceutical entrepreneurs who have built fortunes through scientific innovation and commercial execution. His peers include:

• Christine Franken & family — Known for their work in biopharmaceuticals, particularly in Europe, where they have leveraged academic research into scalable therapeutic platforms.
• Karin Sartorius-Herbst — A German biotech executive whose career spans drug development and corporate strategy, with a focus on translating lab discoveries into market-ready products.
• Kiran Mazumdar-Shaw — Founder of Biocon, India’s largest biopharmaceutical company, and a pioneer in biosimilars and affordable biologics for emerging markets. Like Park, she combines scientific training with entrepreneurial drive to disrupt global healthcare.

These individuals share common traits: deep scientific backgrounds, strategic licensing acumen, and the ability to navigate complex regulatory environments. While their geographic footprints differ — Europe, India, and South Korea — their impact on the global biotech landscape is comparable. Park’s partnership with Merck places him in the same tier as peers who have secured deals with multinational pharmaceutical giants, a key milestone for any biotech founder.

Park Soon-jae’s early life and education laid the foundation for his later success in biotechnology. He earned a Ph.D. from Purdue University, a U.S. institution with a strong reputation in engineering and life sciences. This academic training likely provided him with the technical depth and research discipline necessary to navigate the complex field of biopharmaceuticals. After completing his doctorate, Park pursued postdoctoral research at MIT, one of the world’s leading centers for scientific innovation. This experience would have exposed him to cutting-edge research methodologies and a global network of scientists and entrepreneurs.

Prior to co-founding Alteogen in 2008, Park held positions at LG Life Sciences and Hanwha Petrochemical — two major South Korean conglomerates with significant operations in chemicals and pharmaceuticals. These roles likely gave him practical experience in industrial R&D, regulatory compliance, and large-scale manufacturing — skills that would prove invaluable when launching a biotech startup. Working within established corporations may have also provided him with insights into the challenges of bringing new drugs to market, including the need for scalable, cost-effective delivery systems.

While specific details about his childhood, family background, or early career aspirations are not disclosed in the provided data, his educational and professional trajectory suggests a deliberate path toward biotechnology entrepreneurship. His decision to return to South Korea after studying and working in the U.S. reflects a broader trend of Korean scientists and engineers leveraging global training to build domestic innovation ecosystems. The timing of Alteogen’s founding — 2008 — coincides with a period of increased government support for biotech in South Korea, which may have created a favorable environment for his venture.

At 71 years old as of 2025, Park’s career spans over four decades, during which he transitioned from academic research to industrial R&D and finally to entrepreneurial leadership. This longevity is notable in an industry where many founders are much younger, and it suggests a deep, sustained commitment to biotech innovation. His wife, Chung Hye-shin, who serves as Chief Scientific Officer at Alteogen, indicates a shared professional and personal dedication to the company’s mission — a dynamic that is not uncommon among biotech founding teams but adds a unique dimension to Park’s story.

Park Soon-jae’s path to wealth is a textbook example of biotech entrepreneurship: a scientist-turned-entrepreneur who identified a technical gap in drug delivery, developed a proprietary solution, and licensed it to a global pharmaceutical giant. His journey began with academic training at Purdue University and MIT, followed by industrial experience at LG Life Sciences and Hanwha Petrochemical. These roles provided him with the technical expertise and industry knowledge necessary to launch Alteogen in 2008, a time when South Korea’s biotech sector was still emerging.

The core of Park’s wealth creation lies in Alteogen’s development of ALT-B4, an enzyme technology that enables subcutaneous administration of biologics. This innovation addresses a major limitation in current biologic therapies, which often require intravenous infusion — a time-consuming, costly, and inconvenient process for patients. By enabling subcutaneous delivery, ALT-B4 has the potential to improve patient adherence, reduce healthcare costs, and expand the market for biologic drugs. The technology’s value was validated in 2024 when Merck, a global pharmaceutical leader, agreed to license ALT-B4 for use with pembrolizumab, a blockbuster cancer immunotherapy.

The Merck deal was a watershed moment for Alteogen and for Park’s personal wealth. While the financial terms were not disclosed, such licensing agreements typically include upfront payments, milestone payments tied to clinical and regulatory progress, and royalties on future sales. The immediate 25% surge in Alteogen’s stock price following the announcement suggests that investors viewed the deal as a major de-risking event, validating the technology’s commercial potential. For Park, this translated into a significant increase in paper wealth, assuming he retained a substantial equity stake in the company.

Unlike traditional entrepreneurs who build companies around products or services, Park’s wealth is tied to intellectual property and licensing — a model that requires minimal capital expenditure but offers high upside if the technology is adopted by major pharmaceutical companies. This approach is common in biotech, where the cost of drug development is prohibitive for most startups, and partnerships with larger firms are often the only path to commercialization. Park’s success with ALT-B4 demonstrates the power of this model: a single innovation, licensed to a global player, can generate billions in value for the licensor.

Looking ahead, Park’s wealth will likely continue to be tied to Alteogen’s performance. Future growth will depend on whether the company can secure additional licensing deals, expand ALT-B4’s application to other drug classes, or develop new technologies in-house. His age — 71 as of 2025 — may also influence his strategy, potentially leading to partial exits or succession planning, though no such actions are disclosed in the provided data. Regardless of future developments, Park’s story is a testament to the potential of biotech entrepreneurship in emerging markets — and the transformative power of a single, well-executed innovation.

Park Soon-jae’s empire is anchored in Alteogen, a South Korean biotech firm specializing in biosimilars and bio-betters — a niche that sits at the intersection of cost efficiency and therapeutic innovation. Unlike broad-spectrum pharma giants, Alteogen’s value proposition hinges on proprietary delivery technologies, most notably ALT-B4, which enables subcutaneous administration of drugs traditionally delivered intravenously. This innovation reduces patient burden, hospital dependency, and overall treatment costs — a compelling value proposition for global payers and providers. The 2024 licensing deal with Merck for pembrolizumab — a blockbuster cancer drug — validated Alteogen’s platform and triggered a 25% single-day stock surge, signaling market confidence in its technological moat. However, the empire remains narrowly concentrated: Alteogen’s valuation and growth trajectory are disproportionately tied to the success of ALT-B4 and its adoption by partners like Merck. This creates a single-point-of-failure risk — if regulatory hurdles, manufacturing scalability issues, or competitive alternatives emerge, the entire enterprise could face material headwinds.

Park Soon-jae’s leadership style reflects a hybrid of academic rigor and entrepreneurial pragmatism. With a Ph.D. from Purdue and postdoctoral experience at MIT, he brings scientific credibility to the C-suite — a rare trait in biotech where commercial acumen often overshadows technical depth. His tenure at LG Life Sciences and Hanwha Petrochemical suggests an ability to navigate large corporate bureaucracies before pivoting to startup agility. As CEO and co-founder, Park likely operates with a long-term, R&D-driven mindset, prioritizing platform technology over quick commercial wins. The presence of his wife, Chung Hye-shin, as Chief Scientific Officer, introduces a familial governance layer — potentially enhancing alignment but also raising questions about board independence and succession planning. His leadership appears low-profile, focused on execution rather than public persona, which may insulate the company from reputational volatility but also limit its ability to mobilize external capital or political goodwill during crises.

Capital allocation at Alteogen under Park Soon-jae appears strategically focused on R&D and platform development rather than shareholder returns or diversification. The company’s core asset — ALT-B4 — represents a capital-intensive, high-risk, high-reward bet on delivery technology. The Merck licensing deal suggests Park successfully monetized early-stage innovation without diluting control, a hallmark of disciplined capital allocation. However, the lack of public disclosure on reinvestment rates, capex plans, or geographic expansion raises questions about scalability. With a $3B net worth and no indication of significant personal diversification, Park’s wealth is tightly coupled to Alteogen’s equity performance — a concentration risk that could amplify personal and corporate volatility during market downturns or regulatory setbacks. The absence of dividend policy or share buybacks further suggests a growth-at-all-costs mentality, which may appeal to venture investors but could alienate institutional holders seeking yield or stability.

Alteogen and Park Soon-jae face multiple risk vectors. Regulatory exposure is paramount: biosimilars and bio-betters operate in a heavily scrutinized space where approval timelines, patent challenges, and payer reimbursement policies can make or break commercial viability. The ALT-B4 platform, while innovative, must navigate complex FDA and EMA pathways — delays or rejections could derail partnerships and valuation. Geopolitical risk is also present: as a South Korean firm with global ambitions, Alteogen is vulnerable to trade tensions, supply chain disruptions, and IP theft concerns, particularly in markets like China or the U.S. Reputational risk stems from the familial governance structure — Chung Hye-shin’s dual role as CSO and spouse may invite scrutiny over conflict of interest, even if no misconduct is alleged. Additionally, the company’s reliance on a single technology platform creates operational fragility — if ALT-B4 fails to scale or faces competitive obsolescence, Alteogen’s entire business model could collapse. Lastly, Park’s advanced age (71) and lack of public succession planning introduce continuity risk that could spook investors during leadership transitions.

Public records show no significant philanthropic activity tied to Park Soon-jae or Alteogen. Unlike many biotech billionaires who fund research institutes, patient advocacy groups, or global health initiatives, Park’s profile remains strictly commercial. This absence may reflect cultural norms in South Korea’s biotech sector, where philanthropy is less institutionalized than in the U.S. or Europe, or it may indicate a strategic choice to reinvest all capital into R&D. However, the lack of visible social impact could become a reputational liability as ESG investing gains traction — stakeholders may question the company’s commitment to broader societal value beyond shareholder returns. In the long term, establishing a foundation or partnering with academic institutions could enhance Alteogen’s legacy and mitigate regulatory or public backlash during crises.

Park Soon-jae’s political influence appears minimal, at least publicly. Unlike some Korean chaebol leaders who wield significant sway over policy, Park operates in a highly technical, globally regulated sector where government influence is indirect — through R&D grants, patent law, and healthcare reimbursement policies. South Korea’s government has prioritized biotech as a strategic industry, which may provide Alteogen with favorable regulatory tailwinds or funding opportunities. However, Park’s low public profile and lack of political donations or advisory roles suggest he avoids overt political engagement. This could be a strength — insulating the company from political risk — or a weakness — limiting access to policy levers that could accelerate market access or protect IP. As Alteogen expands globally, particularly into the U.S. and EU, navigating political landscapes will become more critical, and Park’s current apolitical stance may need recalibration.

Park Soon-jae’s legacy will likely be defined by his role in democratizing drug delivery — transforming intravenous therapies into subcutaneous alternatives that improve patient quality of life and reduce healthcare costs. If ALT-B4 becomes a standard platform for biologics, his name will be etched in biotech history alongside pioneers of biosimilars and drug delivery systems. However, legacy durability hinges on more than technological innovation: it requires sustainable governance, successful succession, and global adoption. The familial leadership structure, while potentially cohesive, risks being perceived as insular or nepotistic — a narrative that could tarnish his reputation if Alteogen falters. His academic pedigree and corporate experience lend credibility, but without institutionalizing leadership beyond his tenure, his legacy may be seen as a personal achievement rather than a scalable, enduring enterprise. Ultimately, Park’s legacy will be judged not just by Alteogen’s market cap, but by how widely its technology is adopted and how equitably it benefits patients worldwide.

• Profile: Park Soon-jae —
• Alteogen Corporate Website — https://www.alteogen.com
• Merck Licensing Deal Announcement (2024) — Press Release Archive
• South Korean Biotech Regulatory Framework — Ministry of Food and Drug Safety